Jordan Scott 4/A
4/A · Salarius Pharmaceuticals, Inc. · Filed Sep 13, 2019
Insider Transaction Report
Form 4/AAmended
Jordan Scott
Chief Financial Officer
Transactions
- Award
Stock Option (right to buy)
2019-09-10+10,000→ 10,000 totalExercise: $8.00Exp: 2029-09-10→ Common Stock (10,000 underlying)
Footnotes (1)
- [F1]The grant has a 4-year vesting schedule with 25% vesting on September 30, 2020 and 1/12th of the balance vesting on the last day of each calendar quarter thereafter.